An overview of two comparative multicentre trials with halometasone/triclosan cream in acute superficial bacterial skin infections.
Two multicentre, open comparative trials were carried out by seven dermatologists in Spain and Yugoslavia in 220 evaluable patients with acute superficial skin infections. In these trials halometasone/triclosan cream showed an overall success rate ('good' and 'very good' results) of 84% as against 60% obtained with the comparative preparations. With regard to therapeutic effect halometasone/triclosan cream proved significantly superior to fluocinolone acetonide/neomycin cream (p less than 0.001) and yielded a higher overall success rate, although not statistically significant, than that observed with fluprednylidene acetate/gentamicin/chlorohydroxyquinoline cream (75% versus 57%). The halometasone/triclosan cream was well tolerated: the incidence of unwanted effects was significantly lower (p less than 0.05) than that with fluocinolone acetonide/neomycin cream and equal to that with fluprednylidene acetate/gentamicin/chlorohydroxyquinoline cream.